German regulator puts UniQure gene therapy appraisal on hold

April 17, 2015 9:36 AM

8 0

FRANKFURT, April 17 (Reuters) - A German regulator for new drugs has suspended the assessment of the Western world's first gene therapy, UniQure's Glybera, after an adviser to the European drugs watchdog voiced concern over the treatment.

Glybera, designed to treat a very rare blood disease, came with a preliminary price tag of 1.1 million euros ($1.2 million), before standard German drug pricing discounts.

Also read: German ex-Chancellor Kohl wins privacy violation lawsuit

Read more

To category page